Ocular fundus diseases such as diabetic macular edema (DME), retinal vein occlusion (RVO), and neovascular age-related macular degeneration (nAMD)
Conditions
Interventions
Observation Group:None
Sponsors
The First People's Hospital of Xuzhou
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Only patients who meet all the following inclusion criteria will be eligible for data collection in this study: 1. Patients have signed the informed consent form, volunteered to participate in this study, and have the willingness and ability to cooperate with data collection herein. 2. Patients have a clinical diagnosis of ocular fundus diseases such as diabetic macular edema (DME), retinal vein occlusion (RVO), and neovascular age-related macular degeneration (nAMD); 3. A prescription for the biosimilar ranibizumab was issued at the time of enrollment in the study. (The decision to prescribe the biosimilar ranibizumab shall be made by the attending physician and shall not be influenced by this study.)
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria are prohibited from being enrolled in this study: The patient is undergoing or planning to participate in other clinical interventional studies. The patient is unable to understand the nature of this study or has not provided informed consent. The investigator determines that the patient is otherwise unsuitable for enrollment in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in BCVA (Best-Corrected Visual Acuity) before and after treatment;Changes in CST (Central Subfield Thickness) before and after treatment;Economy; | — |
Countries
China
Contacts
Public ContactLi Suyan
The First People's Hospital of Xuzhou
Outcome results
None listed